Search

Chymopapain

[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.

Leucovorin

Leucovorin, also known as folinic acid or citrovorum factor, is a reduced form of folic acid that serves as a vital coenzyme in nucleic acid synthesis. … [L56091, L56092] Historically developed in 1945, leucovorin has long been a staple on the World Health Organization’s List of Essential Medicines.

Apalutamide

In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth.

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.

Curcumin sulfate

Daptomycin

[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal … Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA

Lomustine

An alkylating agent of value against both hematologic malignancies and solid tumors.

Sotorasib

Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.

Prasugrel

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. … As a result, inhibition of ADP-mediated platelet activation and aggregation occurs.

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. … [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020,[L22619] the FDA fully approved